TRANSCRIPT: An open label, controlled, randomized multicentric international study evaluating the benefit of autologous stem cell transplantation after complete response in frontline setting patients with T cell-lymphoma

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501710-62-02

Acronym

TRANSCRIPT

Enrollment

204

Registered

2023-04-03

Start date

2023-06-07

Completion date

Unknown

Last updated

2026-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral T-cell lymphoma (PTCL)

Brief summary

Modified progression-free survival (mPFS)

Detailed description

Overall survival (OS), Overall response rate (ORR) according to the IWC (International Workshop Criteria) Lugano 2014, Complete response rate (CRR) according to the IWC (International Workshop Criteria) Lugano 2014, Duration of Response (DoR)

Interventions

DRUGDoxorubicin Accord Healthcare 2 mg/ml solution à diluer pour perfusion

DRUGMETHYLPREDNISOLONE VIATRIS 40 mg

DRUGpoudre pour solution injectable (IM-IV)

DRUGCORTANCYL 20 mg

DRUGcomprimé sécable

DRUGVEPESID 100 mg capsule molle

DRUGADCETRIS 50 mg powder for concentrate for solution for infusion

DRUGVINCRISIN 1 mg/ml solution injectable

DRUG1 mg

DRUGCyclofosfamide Accord 500 mg poudre pour solution injectable/pour perfusion

DRUGEtoposide Accord Healthcare 20 mg/ml Solution à diluer pour perfusion

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Modified progression-free survival (mPFS)	—

Secondary

Measure	Time frame
Overall survival (OS), Overall response rate (ORR) according to the IWC (International Workshop Criteria) Lugano 2014, Complete response rate (CRR) according to the IWC (International Workshop Criteria) Lugano 2014, Duration of Response (DoR)	—

Countries

Belgium, France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026